Cotte Laurent, Cua Eric, Reynes Jacques, Raffi François, Rey David, Delobel Pierre, Gagneux-Brunon Amandine, Jacomet Christine, Palich Romain, Laroche Hélène, Cabie André, Hoen Bruno, Chidiac Christian, Pradat Pierre
Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon.
INSERM U1052, Lyon.
Liver Int. 2018 Jun 30. doi: 10.1111/liv.13922.
BACKGROUND & AIMS: HCV incidence still appears on the rise in HIV-infected MSM in France. We assessed the incidence of HCV infection in HIV-positive and in preexposure prophylaxis (PrEP)-using MSM.
HIV-infected, HCV-negative MSM with serological follow-up in 2016 and HIV-negative, HCV-negative PrEP-using MSM enrolled from January 2016 to May 2017 in the French Dat'AIDS cohort were analyzed to assess the incidence of a primary HCV infection. The incidence of HCV reinfection was also determined in patients having cured a previous infection.
Among 10,049 HIV-infected MSM followed in 2016, 681 patients were already HCV-infected when entering the study (prevalence 6.8%). Serological follow-up was available in 2016 for 4,151 HCV-negative patients. Virological follow-up was available for 478 patients who had cured a previous infection. Fifty-seven HCV infections occurred in 2016 (42 primary infections, 15 reinfections). Incidence of primary HCV infection, reinfection and overall HCV infection was respectively 1.0, 3.1 and 1.2/100 person-years (PY). From January 2016 to May 2017, 930 HIV-negative subjects were enrolled for PrEP. Seventeen patients were already HCV-infected (prevalence 1.8%). Twelve HCV infections occurred during follow-up (10 primary infections, 2 reinfections) giving an incidence of primary infection of 1.0/100 PY and an overall incidence of 1.2/100 PY.
The overall incidence of HCV infection and of a primary HCV infection in HIV-positive and in PrEP-using MSM appeared similar in France in 2016-early 2017. HIV-positive and PrEP-using MSM probably share similar at-risk practices and both should be targeted for preventative interventions. This article is protected by copyright. All rights reserved.
在法国,感染人类免疫缺陷病毒(HIV)的男男性行为者(MSM)中丙型肝炎病毒(HCV)的发病率似乎仍在上升。我们评估了HIV阳性以及采用暴露前预防(PrEP)的MSM中HCV感染的发病率。
对2016年接受血清学随访的HIV感染、HCV阴性的MSM以及2016年1月至2017年5月在法国Dat'AIDS队列中入组的HIV阴性、HCV阴性且采用PrEP的MSM进行分析,以评估原发性HCV感染的发病率。还对既往感染已治愈的患者的HCV再感染发病率进行了测定。
在2016年随访的10049例HIV感染的MSM中,681例患者在进入研究时已感染HCV(患病率6.8%)。2016年有4151例HCV阴性患者可进行血清学随访。478例既往感染已治愈的患者可进行病毒学随访。2016年发生了57例HCV感染(42例原发性感染,15例再感染)。原发性HCV感染、再感染以及总体HCV感染的发病率分别为1.0、3.1和1.2/100人年(PY)。从2016年1月至2017年5月,930例HIV阴性受试者入组接受PrEP。17例患者已感染HCV(患病率1.8%)。随访期间发生了12例HCV感染(10例原发性感染,2例再感染),原发性感染发病率为1.0/100 PY,总体发病率为1.2/100 PY。
在2016年至2017年初的法国,HIV阳性以及采用PrEP的MSM中HCV感染和原发性HCV感染的总体发病率似乎相似。HIV阳性和采用PrEP的MSM可能有相似的高危行为,两者都应成为预防性干预的目标人群。本文受版权保护。保留所有权利。